- Lowest price entry point ($69/mo) in the GLP-1 telehealth market
- Available in all 50 states
- Fast, simple digital-first signup process
- No insurance required
- Strong brand recognition — good for people who value name familiarity
- Can transition to brand-name medications with insurance
- Compounded oral semaglutide pill DISCONTINUED in Feb 2026 (FDA pressure + Novo Nordisk lawsuit)
- No structured behavioral coaching program
- No registered dietitian or health coaching included
- Compounded injection availability uncertain post-FDA shortage status change
- Legal controversy surrounding compounded medication marketing
- Limited clinical depth compared to Calibrate and Ro
| Scoring Criterion | Score / 10 |
|---|---|
| Clinical Effectiveness | 5.5 |
| Cost & Transparency | 7.0 |
| Program Comprehensiveness | 4.0 |
| Accessibility & Convenience | 8.5 |
| Customer Satisfaction | 5.5 |
What They Offer
Hims & Hers GLP-1 program offers online consultations with licensed providers and access to compounded semaglutide injections. Previously offered an oral semaglutide pill at $69/mo (now discontinued). The program is primarily digital-first — minimal coaching, no structured curriculum. Focus is on accessibility and low price rather than comprehensive support.
Pricing & Plans
| Plan | Price | Includes |
|---|---|---|
| Compounded Semaglutide Injection | $99-$199/mo | Monthly supply, prescription, basic provider messaging |
| Oral Semaglutide (DISCONTINUED) | N/A — discontinued Feb 2026 | Product was withdrawn under FDA pressure and lawsuit |
| Brand-Name Medication | $299+/mo or via insurance | Wegovy or Ozempic with insurance billing support |
What's Included
- Online intake and consultation with licensed provider
- Prescription for compounded semaglutide injection (subject to availability)
- Monthly medication delivery
- Provider messaging via app (async — not dedicated coach)
- Basic app access
- No structured coaching or behavioral curriculum
Eligibility
BMI 27+ with a weight-related condition OR BMI 30+. Must be 18+. Available in all 50 states. Standard GLP-1 contraindications apply (no history of medullary thyroid cancer, MEN2, pancreatitis history).
Clinical Results & Effectiveness
Hims & Hers does not publish member outcomes data publicly. Their marketing cites clinical trial data for semaglutide generally, not specific program outcomes. The absence of coaching or behavioral support may reduce real-world results compared to programs with structured lifestyle components. Independent data on Hims & Hers GLP-1 patient outcomes is not available at this time.
Customer Experience
User reviews are polarized. Patients who want a simple, low-cost solution report positive experiences with medication delivery and ease of use. Patients seeking more guidance report frustration with the lack of coaching and difficulty reaching support. The recent product discontinuations have generated negative press coverage and customer complaints. Trustpilot: 3.8/5. BBB: B (significant complaint volume). App Store (Hims/Hers): 4.6/5.
Our Verdict
Hims & Hers entered the GLP-1 market aggressively with the lowest prices and widest reach, but a series of setbacks in early 2026 have significantly damaged their product offering. The discontinuation of their compounded oral semaglutide pill — their flagship low-cost product — following FDA pressure and a lawsuit by Novo Nordisk represents a major program change. If you're looking for the most affordable injection-based option and don't need coaching, Hims & Hers may still work. But most patients will find better value and safer clinical footing with Ro or Found.
Get Started →Disclosures
Affiliate Disclosure: GLP1Authority.com may earn commissions from referrals or affiliate partnerships. This review reflects our independent assessment and does not influence our ratings.
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. Please consult with a healthcare provider before starting any GLP-1 weight loss program.